Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2004 1
2005 1
2006 3
2007 5
2008 1
2009 1
2010 3
2011 1
2012 3
2013 5
2014 5
2015 4
2016 9
2017 6
2018 5
2019 2
2020 2
2021 6
2022 8
2023 5
2024 4
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline.
Winkelman JW, Berkowski JA, DelRosso LM, Koo BB, Scharf MT, Sharon D, Zak RS, Kazmi U, Falck-Ytter Y, Shelgikar AV, Trotti LM, Walters AS. Winkelman JW, et al. J Clin Sleep Med. 2025 Jan 1;21(1):137-152. doi: 10.5664/jcsm.11390. J Clin Sleep Med. 2025. PMID: 39324694
In adults with RLS, the AASM suggests against the use of bupropion for the treatment of RLS (conditional recommendation, moderate certainty of evidence). 16. ...SPECIAL ADULT POPULATIONS WITH RLS: 21. In adults with RLS and end-stage renal disease (ESR …
In adults with RLS, the AASM suggests against the use of bupropion for the treatment of RLS (conditional recommendation, moder …
Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.
Winkelman JW, Berkowski JA, DelRosso LM, Koo BB, Scharf MT, Sharon D, Zak RS, Kazmi U, Carandang G, Falck-Ytter Y, Shelgikar AV, Trotti LM, Walters AS. Winkelman JW, et al. J Clin Sleep Med. 2025 Jan 1;21(1):153-199. doi: 10.5664/jcsm.11392. J Clin Sleep Med. 2025. PMID: 39324664
The task force provided a detailed summary of the evidence along with the certainty of evidence, the balance of benefits and harms, patient values and preferences, and resource use considerations. CITATION: Winkelman JW, Berkowski JA, DelRosso LM, et al. Treatment of restl …
The task force provided a detailed summary of the evidence along with the certainty of evidence, the balance of benefits and harms, patient …
Improvement in self-reported, but not actigraphic, sleep measures with suvorexant in people with well-controlled Restless Legs Syndrome and persistent insomnia.
Winkelman JW, Zackon J, Kilty A. Winkelman JW, et al. Sleep Med. 2024 Dec;124:30-37. doi: 10.1016/j.sleep.2024.09.005. Epub 2024 Sep 8. Sleep Med. 2024. PMID: 39260076 Clinical Trial.
BACKGROUND: Sleep disturbance remains common in people with Restless Legs Syndrome (RLS), even after RLS symptoms are sufficiently controlled with medication. We conducted a placebo-controlled crossover trial to examine the efficacy of suvorexant in improving sleep …
BACKGROUND: Sleep disturbance remains common in people with Restless Legs Syndrome (RLS), even after RLS symptoms are sufficie …
Rethinking clinical trials in restless legs syndrome: A roadmap.
Garcia-Borreguero D, Black J, Earley CJ, Fulda S, Högl B, Manconi M, Ondo W, Roth T, Trenkwalder C, Winkelman JW; International Restless Legs Syndrome Study Group (IRLSSG). Garcia-Borreguero D, et al. Sleep Med Rev. 2024 Oct;77:101978. doi: 10.1016/j.smrv.2024.101978. Epub 2024 Jul 18. Sleep Med Rev. 2024. PMID: 39102777 Review.
The number of large clinical trials of restless legs syndrome (RLS) have decreased in recent years, this coincides with reduced interest in developing and testing novel pharmaceuticals. ...Lastly, new populations should be investigated to develop targeted treatments such a …
The number of large clinical trials of restless legs syndrome (RLS) have decreased in recent years, this coincides with reduced inter …
Clinical efficacy and safety of intravenous ferric carboxymaltose for treatment of restless legs syndrome: a multicenter, randomized, placebo-controlled clinical trial.
Earley CJ, García-Borreguero D, Falone M, Winkelman JW. Earley CJ, et al. Sleep. 2024 Jul 11;47(7):zsae095. doi: 10.1093/sleep/zsae095. Sleep. 2024. PMID: 38625730 Clinical Trial.
STUDY OBJECTIVES: Iron therapy is associated with improvements in restless legs syndrome (RLS). This multicenter, randomized, double-blind study evaluated the effect of intravenous ferric carboxymaltose (FCM) on RLS. ...Ongoing RLS medication was tapered star …
STUDY OBJECTIVES: Iron therapy is associated with improvements in restless legs syndrome (RLS). This multicenter, randomized, double- …
Prevalence of Current Restless Legs Syndrome Symptoms Among Patients Treated with Buprenorphine/Naloxone for Opioid Use Disorder.
Wipper B, Cooke MP, Winkelman JW. Wipper B, et al. Nat Sci Sleep. 2023 Oct 21;15:851-859. doi: 10.2147/NSS.S427403. eCollection 2023. Nat Sci Sleep. 2023. PMID: 37886689 Free PMC article.
Of the 17 participants with definite/probable RLS symptoms, just four were taking a medication commonly used to alleviate RLS. An additional 7.0% had possible RLS symptoms. ...Most patients with definite/probable current RLS symptoms did not report tak …
Of the 17 participants with definite/probable RLS symptoms, just four were taking a medication commonly used to alleviate RLS. …
Restless legs syndrome, neuroleptic-induced akathisia, and opioid-withdrawal restlessness: shared neuronal mechanisms?
Ferré S, Winkelman JW, García-Borreguero D, Belcher AM, Chang JH, Earley CJ. Ferré S, et al. Sleep. 2024 Mar 11;47(3):zsad273. doi: 10.1093/sleep/zsad273. Sleep. 2024. PMID: 37864837 Free PMC article.
Restlessness is a core symptom underlying restless legs syndrome (RLS), neuroleptic-induced akathisia, and opioid withdrawal. These three conditions also share other clinical components suggesting some overlap in their pathophysiology. Recent prospective studies demonstrat …
Restlessness is a core symptom underlying restless legs syndrome (RLS), neuroleptic-induced akathisia, and opioid withdrawal. These t …
Efficacy and safety of tonic motor activation (TOMAC) for medication-refractory restless legs syndrome: a randomized clinical trial.
Bogan RK, Roy A, Kram J, Ojile J, Rosenberg R, Hudson JD, Scheuller HS, Winkelman JW, Charlesworth JD. Bogan RK, et al. Sleep. 2023 Oct 11;46(10):zsad190. doi: 10.1093/sleep/zsad190. Sleep. 2023. PMID: 37458698 Free PMC article. Clinical Trial.
STUDY OBJECTIVES: The purpose of this study was to evaluate the efficacy and safety/tolerability of bilateral high-frequency tonic motor activation (TOMAC) in patients with medication-refractory restless legs syndrome (RLS). METHODS: RESTFUL was a multicenter, randomized, …
STUDY OBJECTIVES: The purpose of this study was to evaluate the efficacy and safety/tolerability of bilateral high-frequency tonic motor act …
Long-term Safety, Dose Stability, and Efficacy of Opioids for Patients With Restless Legs Syndrome in the National RLS Opioid Registry.
Winkelman JW, Wipper B, Zackon J. Winkelman JW, et al. Neurology. 2023 Apr 4;100(14):e1520-e1528. doi: 10.1212/WNL.0000000000206855. Epub 2023 Jan 25. Neurology. 2023. PMID: 36697248 Free PMC article.
BACKGROUND AND OBJECTIVES: Restless legs syndrome (RLS) is a sensory-motor neurologic disorder. Low-dose opioids are prescribed for patients with refractory or augmented RLS. The long-term safety, dose stability, and efficacy of these medications for RLS trea …
BACKGROUND AND OBJECTIVES: Restless legs syndrome (RLS) is a sensory-motor neurologic disorder. Low-dose opioids are prescribed for p …
Consensus guidelines on the construct validity of rodent models of restless legs syndrome.
Salminen AV, Clemens S, García-Borreguero D, Ghorayeb I, Li Y, Manconi M, Ondo W, Rye D, Siegel JM, Silvani A, Winkelman JW, Allen RP, Ferré S; International Restless Legs Syndrome Study Group (IRLSSG). Salminen AV, et al. Dis Model Mech. 2022 Aug 1;15(8):dmm049615. doi: 10.1242/dmm.049615. Epub 2022 Aug 10. Dis Model Mech. 2022. PMID: 35946581 Free PMC article.
As a task force of preclinical and clinical scientists, we have previously defined face validity parameters for rodent models of RLS. In this article, we establish new guidelines for the construct validity of RLS rodent models. ...Investigating these factors, both i …
As a task force of preclinical and clinical scientists, we have previously defined face validity parameters for rodent models of RLS. …
Treating Severe Refractory and Augmented Restless Legs Syndrome.
Winkelman JW. Winkelman JW. Chest. 2022 Sep;162(3):693-700. doi: 10.1016/j.chest.2022.05.014. Epub 2022 May 21. Chest. 2022. PMID: 35609673 Review.
Furthermore, DAs, the most commonly used medications for RLS, commonly produce augmentation, a progressive, long-term, iatrogenic worsening of RLS symptoms characterized by increasing severity as well as temporal and anatomic extension of symptoms. If dopaminergic a …
Furthermore, DAs, the most commonly used medications for RLS, commonly produce augmentation, a progressive, long-term, iatrogenic wor …
Genetic evidence for a potential causal relationship between insomnia symptoms and suicidal behavior: a Mendelian randomization study.
Nassan M, Daghlas I, Winkelman JW, Dashti HS; International Suicide Genetics Consortium; Saxena R. Nassan M, et al. Neuropsychopharmacology. 2022 Aug;47(9):1672-1679. doi: 10.1038/s41386-022-01319-z. Epub 2022 May 10. Neuropsychopharmacology. 2022. PMID: 35538198 Free PMC article.
Insomnia and restless leg syndrome (RLS) are associated with increased risk for suicidal behavior (SB), which is often comorbid with mood or thought disorders; however, it is unclear whether these relationships are causal. We performed a two-sample Mendelian randomization …
Insomnia and restless leg syndrome (RLS) are associated with increased risk for suicidal behavior (SB), which is often comorbid with …
How effective are treatment guidelines for augmented RLS?
Yeung Laiwah J, Winkelman JW. Yeung Laiwah J, et al. Sleep. 2022 Jul 11;45(7):zsac108. doi: 10.1093/sleep/zsac108. Sleep. 2022. PMID: 35532181
Responders did have significantly more severe RLS, more sleep maintenance insomnia, and greater subjective daytime sleepiness at baseline (p < 0.05). CONCLUSIONS: Guideline-based management is effective in most patients with augmented RLS on DAs....
Responders did have significantly more severe RLS, more sleep maintenance insomnia, and greater subjective daytime sleepiness at base …
Restless Legs Syndrome in X-linked adrenoleukodystrophy.
Winkelman JW, Grant NR, Molay F, Stephen CD, Sadjadi R, Eichler FS. Winkelman JW, et al. Sleep Med. 2022 Mar;91:31-34. doi: 10.1016/j.sleep.2022.02.008. Epub 2022 Feb 16. Sleep Med. 2022. PMID: 35245789 Free PMC article.
We sought to investigate the prevalence and severity of Restless Legs Syndrome (RLS) in patients with ALD. PATIENTS/METHODS: We administered questionnaires and conducted diagnostic telephone interviews to assess RLS severity. ...RESULTS AND CONCLUSIONS: Thirty-two a …
We sought to investigate the prevalence and severity of Restless Legs Syndrome (RLS) in patients with ALD. PATIENTS/METHODS: We admin …
Restless legs syndrome severity in the National RLS Opioid Registry during the COVID-19 pandemic.
Wipper B, Romero-Gutierrez C, Winkelman JW. Wipper B, et al. Sleep Med. 2022 Feb;90:96-101. doi: 10.1016/j.sleep.2022.01.011. Epub 2022 Jan 23. Sleep Med. 2022. PMID: 35131547 Free PMC article.
OBJECTIVE/BACKGROUND: No research has yet assessed the impact of the coronavirus disease 2019 (COVID-19) pandemic on restless legs syndrome (RLS). We hypothesized that RLS symptom severity would be increased during the COVID-19 pandemic in a sample of patients with …
OBJECTIVE/BACKGROUND: No research has yet assessed the impact of the coronavirus disease 2019 (COVID-19) pandemic on restless legs syndrome …
High national rates of high-dose dopamine agonist prescribing for restless legs syndrome.
Winkelman JW. Winkelman JW. Sleep. 2022 Feb 14;45(2):zsab212. doi: 10.1093/sleep/zsab212. Sleep. 2022. PMID: 34417810 Free PMC article.
STUDY OBJECTIVES: Long-term dopamine agonist (DA) use in restless legs syndrome (RLS) is associated with augmentation, a dose-related symptom worsening leading to further dose escalation to manage RLS. ...Increased education is warranted regarding risks of high-dose …
STUDY OBJECTIVES: Long-term dopamine agonist (DA) use in restless legs syndrome (RLS) is associated with augmentation, a dose-related …
76 results